This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ciprofloxacin auricular

Updated 2 Feb 2023 | Anti-infective preparations


Ear drops containing ciprofloxacin preservative-free.

Drugs List

  • CETRAXAL 2mg/ml ear drops 0.25ml unit dose
  • ciprofloxacin 2mg/ml ear drops preservative-free 0.25ml unit dose
  • Therapeutic Indications


    Acute otitis externa



    Instil the contents of 1 dose unit into the affected ear twice daily.


    Instil the contents of 1 dose unit into the affected ear twice daily.


    None known

    Precautions and Warnings

    Children under 1 year
    Suspected tympanic membrane perforation
    Perforated tympanic membrane

    Prolonged use may result in superinfection with non-susceptible organisms
    Discontinue if drug-related rash or other hypersensitivity reactions occur

    Pregnancy and Lactation


    Ciprofloxacin ear drops are considered safe for use in pregnancy.

    The manufacturer notes that although there is little data on the use of ciprofloxacin otic solution in pregnant women, animal studies do not indicate direct/indirect harmful effects relating to reproductive toxicity. Systemic exposure to ciprofloxacin after otic administration is negligible.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Ciprofloxacin ear drops are considered safe for use in breastfeeding.

    The manufacturer notes that it is unknown if ciprofloxacin is excreted in human milk after otic use but since the exposure of ciprofloxacin to breastfeeding women is negligible, no effects on the breastfed infant are anticipated.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Ear pruritus
    Exfoliative dermatitis
    Pain at application site
    Stevens-Johnson syndrome


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2018

    Reference Sources

    Summary of Product Characteristics: Cetraxal 2mg/ml ear drops, solution single-dose container. Aspire Pharma Ltd. Revised October 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.